Latest Ratios: P/E Ratio -4.5x · EV/EBITDA N/A · ROE -16.7%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $351M | $488M | $617M | $175M | $92M | $297M | $432M | $232M | $342M | $194M | $211M |
| Enterprise Value | $264M | $401M | $483M | $221M | $113M | $380M | $459M | $271M | $418M | $331M | $371M |
| P/E Ratio → | -4.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.11 | 5.72 | 3.54 | 1.65 | 0.94 | 2.28 | 3.13 | 1.98 | 3.03 | 1.91 | 2.02 |
| P/B Ratio | 0.81 | 1.15 | 1.31 | — | — | 3.14 | 3.11 | 1.51 | 4.74 | 6.28 | 3.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.70 | 2.77 | 2.08 | 1.15 | 2.91 | 3.32 | 2.31 | 3.70 | 3.25 | 3.55 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.9% | 49.9% | 48.3% | 47.4% | 37.8% | 53.1% | 60.3% | 54.8% | 54.6% | 51.0% | 55.9% |
| Operating Margin | -109.3% | -109.3% | -100.5% | -72.0% | -118.6% | -51.7% | -36.9% | -44.2% | -42.6% | -57.3% | -70.1% |
| Net Profit Margin | -87.8% | -87.8% | -79.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% | -52.2% | -59.4% | -72.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.7% | -16.7% | -85.8% | — | -2895.8% | -50.7% | -36.2% | -57.4% | -114.5% | -143.8% | -90.4% |
| ROA | -12.7% | -12.7% | -29.7% | -20.9% | -57.1% | -19.7% | -18.0% | -22.8% | -20.0% | -20.4% | -22.4% |
| ROIC | -20.7% | -20.7% | -111.2% | — | -148.1% | -29.4% | -21.4% | -22.8% | -22.8% | -23.0% | -22.2% |
| ROCE | -18.6% | -18.6% | -46.1% | -27.3% | -40.6% | -27.2% | -20.3% | -20.8% | -18.5% | -22.0% | -23.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.07 | — | — | 1.18 | 0.69 | 0.39 | 2.39 | 6.31 | 3.66 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.28 | — | — | 0.88 | 0.19 | 0.25 | 1.06 | 4.43 | 3.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3718.31 | -3718.31 | -40.71 | -15.25 | -43.55 | -15.65 | -14.15 | -14.59 | -3.42 | -9.95 | -12.78 |
Net cash position: cash ($118M) exceeds total debt ($31M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.19 | 4.19 | 5.70 | 1.45 | 4.81 | 1.45 | 2.17 | 2.93 | 3.38 | 2.83 | 3.28 |
| Quick Ratio | 4.01 | 4.01 | 5.09 | 1.26 | 4.31 | 1.03 | 1.81 | 2.50 | 3.04 | 2.38 | 2.60 |
| Cash Ratio | 1.73 | 1.73 | 4.44 | 1.05 | 3.82 | 0.57 | 1.26 | 1.79 | 2.54 | 1.89 | 2.01 |
| Asset Turnover | — | 0.15 | 0.28 | 0.33 | 0.25 | 0.47 | 0.43 | 0.44 | 0.37 | 0.35 | 0.34 |
| Inventory Turnover | 2.14 | 2.14 | 2.21 | 2.72 | 2.84 | 2.94 | 2.78 | 3.81 | 3.95 | 3.31 | 2.29 |
| Days Sales Outstanding | — | 57.45 | 70.32 | 67.48 | 64.39 | 51.21 | 67.17 | 59.09 | 53.80 | 53.89 | 51.06 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $382M | $353M | $79M | $78M | $76M | $72M | $67M | $40M | $33M | $29M |
Persistent negative operating margins
Based on reported figures, Standard BioTools trades at a price-to-sales multiple of 3.44, which appears to discount the company's ongoing revenue contraction and suggests that investors are valuing the firm primarily as a speculative asset rather than a growth-oriented life science tool provider.
The absence of a meaningful P/E ratio and negative EBITDA multiples indicate that traditional valuation metrics are currently ineffective for assessing the company's intrinsic value. The market's pricing likely reflects a high degree of skepticism regarding management's ability to achieve profitability, effectively treating the current market capitalization as a proxy for the underlying cash and intellectual property assets.
According to recent financial statements, the company's ROIC has remained consistently negative, reaching -2.8% in 2026Q1, which highlights a structural inability to generate returns on invested capital that exceed the cost of funding in the current high-interest rate environment.
The persistent negative ROIC trend suggests that the capital deployed into the CyTOF and SomaScan platforms has yet to yield the expected operational efficiencies. Investors should monitor whether future capital allocation shifts toward high-margin consumables can reverse this decay, as current returns remain well below the thresholds required for long-term value creation.
As reported in financial filings, the company's cash conversion cycle reached 179 days in 2026Q1, a figure that underscores significant operational friction and suggests that the firm struggles to efficiently convert its inventory of specialized instrumentation into realized cash flows.
The high days-inventory-outstanding, which peaked at 3,925 days in 2025Q4, points to potential obsolescence risks or a mismatch between production capacity and market demand. This inefficiency in working capital management likely exacerbates the company's cash burn, necessitating a more disciplined approach to inventory turnover to improve liquidity.
Based on the provided balance sheet data, the company maintains a current ratio of 12.36 as of 2026Q1, which appears to provide a substantial, albeit temporary, cushion against the ongoing operational losses that continue to erode the firm's core financial stability.
While the high liquidity position may suggest a degree of safety, it is largely a function of recent capital raises and restructuring rather than operational success. This liquidity buffer warrants careful monitoring, as it may be rapidly depleted if the company fails to achieve a sustainable path to positive cash flow in the coming quarters.
Investors frequently misapply price-to-sales multiples to Standard BioTools, failing to account for the company's massive revenue volatility and the structural shift toward a reagent-rental model that obscures the true underlying growth trajectory of the core proteomics business.
Using P/S ratios in this context is misleading because it ignores the high fixed-cost nature of the business and the significant impact of non-recurring divestitures. A more appropriate metric would be the 'pull-through' revenue per installed instrument, which provides a clearer view of the recurring earning power that the market currently fails to isolate.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LAB stock.
Standard BioTools Inc.'s current P/E ratio is -4.5x. This places it at the 50th percentile of its historical range.
Standard BioTools Inc.'s return on equity (ROE) is -16.7%. The historical average is -58.3%.
Based on historical data, Standard BioTools Inc. is trading at a P/E of -4.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Standard BioTools Inc. has 49.9% gross margin and -109.3% operating margin.